XML 59 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Marketable Securities
3 Months Ended
Mar. 31, 2015
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2015
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
664,879

 
$

 
$

 
$
664,879

Total cash and cash equivalents
$
664,879

 
$

 
$

 
$
664,879

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
284,126

 
$
5

 
$
(16
)
 
$
284,115

Commercial paper (due within 1 year)
59,688

 
57

 

 
59,745

Corporate debt securities (due within 1 year)
148,958

 
18

 
(24
)
 
148,952

Corporate debt securities (due after 1 year through 5 years)
23,430

 
13

 

 
23,443

Total marketable securities
$
516,202

 
$
93

 
$
(40
)
 
$
516,255

Total cash, cash equivalents and marketable securities
$
1,181,081

 
$
93

 
$
(40
)
 
$
1,181,134

 
 
 
 
 
 
 
 
As of December 31, 2014
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
625,259

 
$

 
$

 
$
625,259

Total cash and cash equivalents
$
625,259

 
$

 
$

 
$
625,259

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (due within 1 year)
$
463,788

 
$
14

 
$
(52
)
 
$
463,750

Commercial paper (due within 1 year)
51,674

 
72

 

 
51,746

Corporate debt securities (due within 1 year)
196,065

 
2

 
(66
)
 
196,001

Corporate debt securities (due after 1 year through 5 years)
50,443

 

 
(93
)
 
50,350

Total marketable securities
$
761,970

 
$
88

 
$
(211
)
 
$
761,847

Total cash, cash equivalents and marketable securities
$
1,387,229

 
$
88

 
$
(211
)
 
$
1,387,106


The Company has a limited number of marketable securities in insignificant loss positions as of March 31, 2015, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three months ended March 31, 2015 and 2014.